| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.3M | +0.0% |
| Cost of Revenue | $91.5M | +0.0% |
| R&D Expense | $33.3M | +0.0% |
| SG&A Expense | $12.9M | -76.3% |
| Operating Income | -$10.9M | +96.9% |
| Pre-tax Income | -$8.1M | +97.6% |
| Net Income | -$8.1M | +97.6% |
| EPS (Basic) | -$0.67 | +96.9% |
| EPS (Diluted) | -$0.67 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $23.1M | -73.5% |
| Short-term Investments | $6.4M | — |
| Current Assets | $53.2M | -42.3% |
| Total Assets | $53.2M | -42.3% |
| Current Liabilities | $1.1M | -93.1% |
| Total Liabilities | $10.9M | -76.1% |
| Stockholders' Equity | $6.8M | -50.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$35.1M | +74.4% |
| Capital Expenditures | $10.2M | +0.0% |
| Investing Cash Flow | -$28.8M | -128.0% |
| Financing Cash Flow | -$106K | — |
| Free Cash Flow | -$45.2M | +69.3% |
| +96.9% |